# Paul Sargeant

> Paul Sargeant is the President and CEO of Circular Genomics, a San Diego biotech building blood tests around circular RNA - the loop-shaped, unusually stable molecules most of the field once ignored. A Cambridge-trained physiologist with 25 years across Fortune 100 firms and venture-backed startups in the US, Europe and Asia, he took the helm in 2023, shepherded the launch of the MindLight test predicting which depression patients will respond to SSRIs, moved headquarters into Lilly Gateway Labs, and closed a $15M Series A in December 2025 to push the same platform toward early Alzheimer's detection.

- **Role:** President and Chief Executive Officer at Circular Genomics
- **Organizations:** Circular Genomics, Rebus Biosystems
- **Nationality:** British
- **Education:** PhD in Physiology, Queens' College, University of Cambridge
- **Known for:** Over 25 years of life science industry leadership across the US, Europe and Asia, Raised more than $200 million in funding across his career, Launched multiple FDA-regulated devices

## Career timeline

- **earlier** — Held leadership roles across Fortune 100 corporations and venture-backed startups in the US, Europe and Asia Pacific, spanning clinical diagnostics, instrumentation and software
- **before 2023** — CEO of Rebus Biosystems, an Illumina Ventures-backed imaging platform venture in spatial biology
- **2023** — Appointed President and CEO of Circular Genomics (announced April 27, 2023)
- **2024** — Company published research on accuracy of its circRNA-based test predicting SSRI antidepressant response
- **2025** — Relocated headquarters from Albuquerque to Lilly Gateway Labs in San Diego; expanded platform toward Alzheimer's diagnosis and prognosis
- **2025** — Closed $15M Series A led by Mountain Group Partners to advance circular RNA platform for early Alzheimer's detection (December 2025)

## Achievements

- Over 25 years of life science industry leadership across the US, Europe and Asia
- Raised more than $200 million in funding across his career
- Launched multiple FDA-regulated devices
- Led Circular Genomics to launch the MindLight test for major depressive disorder
- Closed a $15M Series A in December 2025 to expand into Alzheimer's diagnostics
- Secured a move into Lilly Gateway Labs in San Diego

## Latest updates

- **2025-12** — Circular Genomics closed a $15M Series A led by Mountain Group Partners, with Poplar Grove Investors, HIP Fund and the Alzheimer's Drug Discovery Foundation participating, to advance its circular RNA platform for early Alzheimer's detection.
- **2025-03** — Company joined Lilly Gateway Labs in San Diego and relocated its headquarters from Albuquerque.

## Links

- Website: https://circulargenomics.com
- LinkedIn: http://www.linkedin.com/in/psargeant
- Twitter/X: https://twitter.com/CircGenomics

---

Profile page: https://yespress.io/paul-sargeant
Published by YesPress — https://yespress.io
Last updated: 2026-06-08